| abstract |
A novel moncyclic L-nucleoside compound L-Ribavirin havingnthe formula (I) is disclosed. This compound is contemplatednto be useful in treating a wide variety of diseases includingninfections, infestations, neoplasms, and autoimmune diseases.nViewed in terms of mechanism, this novel compound showsnimmunomodulatory activity, and is expected to be useful innmodulating the cytokine pattern, including modulation of Th1nand Th2 response. |